Merit
Laufzeit: 01.01.2017 - 31.12.2025
Laufzeit: 01.01.2017 - 31.12.2025
First-in-human Clinical Study with RNA-Immunotherapy Combination of IVAC_W_bre1_ulD and IVAC_M_ulD for individualized Tumor Therapy in triple negative breast cancer patients